RECRUITINGPhase 3INTERVENTIONAL
Novel Regimens in COVID-19 Treatment
Nitazoxanide in Treatment of COVID-19
About This Trial
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with COVID-19 infection
Who Should NOT Join This Trial:
- Allergy or contraindication to the drugs.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with COVID-19 infection
Exclusion Criteria:
* Allergy or contraindication to the drugs.
Treatments Being Tested
DRUG
Nitazoxanide
Nitazoxanide
Locations (2)
Tanta University, Assiut University
Tanta, Egypt
Sherief Abd-Elsalam
Tanta, Egypt